NextCure, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-1.98 | $-1.84 | +7.1% | Beat |
| Q12026 FY2026 | $-1.85 | $-1.87 | -1.1% | Miss |
| Q42025 FY2025 | $-2.26 | $-0.81 | +64.2% | Beat |
Back to NXTC overview · NXTC holders · NXTC KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.